Rate of infection by blood-borne viruses in active heroin users in 3 Spanish cities

被引:17
作者
Bassani, S
Toro, C
de la Fuente, L
Brugal, MT
Jiménez, V
Soriano, V
机构
[1] Hosp Carlos 3, Serv Enfermedades Infecciosas, Madrid, Spain
[2] Inst Salud Carlos III, Plan Nacl Sobre Sida, Minist Sanidad & Consuma, Ctr Nacl Epidemiol, Madrid, Spain
[3] Agcy Salud Publ Barcelona, Barcelona, Spain
来源
MEDICINA CLINICA | 2004年 / 122卷 / 15期
关键词
HIV; hepatitis B; hepatitis C; HTLV; heroin users; IDUs;
D O I
10.1157/13060891
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND AND OBJECTIVE: The objective of this paper was to determine the prevalence of human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) and human T lymphotropic virus (HTLV) infections in active heroin users in Spain. SUBJECTS AND METHOD: A cross-sectional study was carried out in 440 heroin users in three different urban areas of Spain: Barcelona, Madrid, and Seville. Specimens were analyzed for the presence of ani anti-HCV, anti-HBc, and anti-HTLV antibodies. RESULTS: The rate of anti-HIV antibodies was 20% (CI 95%, 16.3-23.7%); anti-HBc: 21.4% (CI 95%, 17.5-25.2%); anti-HCV: 59.1% (CI 95%, 54.5-63.7%); and anti-HTLV (HTLV-II in all cases); 3.4% (CI 95%, 1.7-5.1%). Barcelona and Madrid had similar rates for each virus, yet these were lower in Seville especially with regard to HCV (Barcelona: 59.7% [CI 95%, 53.1-66.3%]; Madrid: 63.8% [CI 95%, 56.7-70.9]; Seville: 41.8% [CI 95%, 28.8-54.9%]). CONCLUSIONS: HCV is the most prevalent infection among active heroin users in Spain. The rate of infection by blood-borne viruses is higher in Madrid and Barcelona than in Seville (notably for HCV), most likely due to a lower rate of intravenous users in this city.
引用
收藏
页码:570 / 572
页数:3
相关论文
共 10 条
[1]  
ALBA A, 2003, ENFERM INFEC MICR CL, V21, P137
[2]   Reasons for selecting an initial route of heroin administration and for subsequent transitions during a severe HIV epidemic [J].
Bravo, MJ ;
Barrio, G ;
de la Fuente, L ;
Royuela, L ;
Domingo, L ;
Silva, T .
ADDICTION, 2003, 98 (06) :749-760
[3]  
BRAVO MJ, 2003, 7 C NAC SID MAYO BIL
[4]  
De la Fuente L, 1997, ADDICTION, V92, P1749, DOI 10.1111/j.1360-0443.1997.tb02895.x
[5]  
de la Fuente L, 1999, MED CLIN-BARCELONA, V113, P646
[6]  
Perez Gonzalez K, 1999, Gac Sanit, V13, P88
[7]   Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy [J].
Quaglio, G ;
Lugoboni, F ;
Pajusco, B ;
Sarti, M ;
Talamini, G ;
Lechi, A ;
Mezzelani, P ;
Jarlais, DCD .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (01) :33-40
[8]  
Taylor GP, 1999, AIDS REV, V1, P195
[9]   HIV-2 and HTLV-I/II infections in Spain [J].
Toro, C ;
Rodés, B ;
Aguilera, A ;
Caballero, E ;
Benito, R ;
Bassani, S ;
Rodríguez, C ;
Tuset, C ;
De Lejarazu, RO ;
Eirós, J ;
García, J ;
Calderón, E ;
Capote, FJ ;
Vallejo, A ;
Gutiérrez, M ;
Soriano, V .
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2004, 22 (03) :177-182
[10]  
TORRESTORTOSA M, 1995, MED CLIN-BARCELONA, V104, P249